Control of Autonomous Underwater Vehicles

In this thesis an overview of Autonomous Underwater Vehicles (AUV) is presented which covers the advancements in AUV technology in last two decades, different components of AUV and the applications of AUVs. A glimpse on AUV research in India is presented. A nonlinear model of AUV is obtained through kinematics and dynamics equation which is linearized about an operating point to get linearized pitch & depth plane model. A two loop controller (PI control) is used to control the pitch and in turn the depth of the AUV. After having developed, simulated and analyzed the pitch and depth controller for a single AUV, we focus our attention towards developing formation control of three AUVs. The formation control for multiple Autonomous Underwater Vehicles (AUVs) is considered in spatial motions.The objective is to drive a leader AUV along a desired trajectory, and make the follower AUVs keep a desired formation with respect to the leader’s configuration in 3-dimensional spaces (leader-follower formation control). Also, an obstacle avoidance scheme, using pitch and depth control, is used to avoid static obstacles in the path of AUV. The results of the above three control objectives such as tracking control of AUV, controller for avoiding obstacles and formation control of multiple AUVs are presented and discussed in the thesis

Hepatitis C, a silent threat to the community of Haryana, India: a community-based study

Background Hepatitis C is a global public health problem. About 12 million persons may be chronically infected in India and most do not know that they are infected. Aims To found out real situation of hepatitis C in Ratia block, district Fatehabad (Haryana). Method This cross sectional study was carried out by house to house visits in 2 weeks time. After obtaining the written consent, blood sample was drawn from suspected case by the laboratory technician maintaining all necessary safety precautions and sterilization. Results 1630 (22.3%) samples were found to be positive for Hepatitis-C by ELISA while 253 (15.5%) patients were previously hepatitis C positive and maximally adults (21–60 years) were affected (70.0%). Conclusion The study emphasizes on public awareness campaigns, where HCV exposure is prevalent i.e. at the health care providers and patient level

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

The Effects of Communication Parameters on End Performance of Shared Virtual Memory Clusters

Recently there has been a lot of effort in providing cost-effective Shared Memory systems by employing software only solutions on clusters of high-end workstations coupled with high-bandwidth, low-latency commodity networks. Much of the work so far has focused on improving protocols, and there has been some work on restructuring applications to perform better on SVM systems. The result of this progress has been the promise for good performance on a range of applications at least in the 16-32 processor range. New system area networks and network interfaces provide significantly lower overhead, lower latency and higher bandwidth communication in clusters, inexpensive SMPs have become common as the nodes of these clusters, and SVM protocols are now quite mature. With this progress, it is now useful to examine what are the important system bottlenecks that stand in the way of effective parallel performance; in particular, which parameters of the communication architecture are most important to improve further relative to processor speed, which ones are already adequate on modern systems for most applications, and how will this change with technology in the future. Such information can assist system designers in determining where to focus their energies in improving performance, and users in determining what system characteristics are appropriate for their applications. We find that the most important system cost to improve is the overhead of generating and delivering interrupts. Improving network interface (and I/O bus) bandwidth relative to processor speed helps some bandwidth-bound applications, but currently available ratios of bandwidth to processor speed are already adequate for many others. Surprisingly, neither the processor overhead for handling messages nor ..

Evaluation of Hardware Write Propagation Support for Next-Generation Shared Virtual Memory Clusters

Clusters of symmetric multiprocessors (SMPs), connected by commodity system-area networks (SANs) and interfaces are fast being adopted as platforms for parallel computing. Page-grained shared virtual memory (SVM) is a popular way to support a coherent shared address space programming model on these clusters. Previous research has identified several key bottlenecks in the communication, protocol and application layers of a software SVM system that are not so significant in more mainstream, hardware-coherent multiprocessors. A key question for the communication layer is how much and what kind of hardware support is particularly valuable in improving the performance of such systems. This paper examines a popular form of hardware support---namely, support for automatic, hardware propagation of writes to remote memories---discussing new design issues and evaluating performance in the context of emerging clusters. Since much of the performance difference is due to differences in contention effects in various parts of the system, performance is examined through very detailed simulation, utilizing the deep visibility into the simulated system to analyze the causes of observed effects

Real-Time Parallel MPEG-2 Decoding in Software

The growing demand for high quality compressed video has led to an increasing need for real-time MPEG decoding at greater resolutions and picture sizes. With the widespread availability of small-scale multiprocessors, a parallel software implementation may provide an effective solution to the decoding problem. We present a parallel decoder for the MPEG standard, implemented on a shared memory multiprocessor. Goal of this work is to provide an all-software solution for real-time, high-quality video decoding and to investigate the important properties of this application as they pertain to multiprocessor systems. Both coarse and fine grained implementations are considered for parallelizing the decoder. The coarse-grained approach exploits parallelism at the group of pictures level, while the fine-grained approach parallelizes within pictures, at the slice level. A comparative evaluation of these methods is made, with results presented in terms of speedup, memory requirements, load balanc..